Efficacy and specific toxicity profiles of GPRC5D- versus BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: a meta-analysis of clinical trials and real-world studies

Front Immunol. 2026 Sep 29;17:1937154. doi: 10.3389/fimmu.2026.1937154. eCollection 2026.ABSTRACTBACKGROUND: Patients with relapsed/refractory multiple myeloma (RRMM) experience poor outcomes following multiple lines of therapy. Available evidence has largely pooled disparate immunotherapy platforms

J Jiahao Ji

Comprehensive metabolomic characterization of patients with myasthenia gravis

Front Immunol. 2026 Sep 29;17:1906581. doi: 10.3389/fimmu.2026.1906581. eCollection 2026.ABSTRACTBACKGROUND: Myasthenia gravis (MG) is mediated by abnormal antibody generation and is characterized by muscle weakness and pathological fatigue. However, the accuracy of anti-acetylcholine receptor (AChR

H Hui Deng